Skip to main content
. 2016 May 13;7(25):37882–37892. doi: 10.18632/oncotarget.9352

Table 2. Patients characteristics.

Patients Age Sex Baseline diagnosis DAC Treatments Response to DAC therapy (after 2 cycles)
UPN1 54 M hepatocellular carcinoma DAC monotherapy SD
UPN2 58 M hepatocellular carcinoma PRFA combined DAC SD
UPN3 54 F carcinoma of uterine tube DAC+chemotherapy SD
UPN4 42 F ovarian cancer DAC+chemotherapy PR